Imago Biosciences
329 Oyster Point Blvd, 3rd Floor
South San Francisco
CA
94080
United States
Tel: 415-529-5055
Website: http://imagobio.com/
39 articles with Imago Biosciences
-
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
1/11/2023
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc.
-
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
12/20/2022
Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO) today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF).
-
Merck initiated a tender offer Monday to buy all outstanding shares of Imago Biosciences. This follows the November announcement of the buyout.
-
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
12/12/2022
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc.
-
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
12/12/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).
-
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
11/30/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML).
-
With a $1.36 billion buyout, Merck bolstered its oncology program with the acquisition of Biotech Bay-based Imago Biosciences, a company focused on chronic bone marrow cancers.
-
Merck to Acquire Imago BioSciences, Inc.
11/21/2022
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.
-
Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates
11/9/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Imago BioSciences to Participate in Upcoming November 2022 Investor Conferences
11/7/2022
Imago BioSciences, Inc. announced that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in two upcoming investor conferences.
-
Imago BioSciences Announces Oral Data Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition
11/3/2022
Imago BioSciences, Inc. announced two abstracts have been accepted for oral presentation at the 64th American Society of Hematology Annual Meeting and Exposition, to be held December 10-13, 2022.
-
Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 - 14, 2022.
-
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
8/12/2022
Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), today reported financial results for the second quarter ended June 30, 2022 and provided business updates.
-
Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference
8/3/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in an analyst led Fireside Chat at the 2022 Wedbush PacGrow Healthcare Conference.
-
Imago's early failed experiments investigating the potential of LSD1 in sickle cell disease and thalassemia have turned out to be fortuitous for patients with myeloproliferative neoplasms.
-
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
6/10/2022
Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia.
-
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022
6/10/2022
Imago BioSciences, Inc. presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis.
-
Imago BioSciences to Host Virtual Investor Event in June 2022
6/6/2022
Imago BioSciences, Inc. announced that a virtual investor event will be hosted by the company’s management team following the company’s presentations at EHA in Vienna, Austria and virtually.
-
Imago BioSciences to Participate in Upcoming Investor Conferences - May 16, 2022
5/16/2022
Imago BioSciences, Inc. announced that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in three upcoming investor conferences.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.